<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJOG</journal-id><journal-title-group><journal-title>Open Journal of Obstetrics and Gynecology</journal-title></journal-title-group><issn pub-type="epub">2160-8792</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojog.2024.141006</article-id><article-id pub-id-type="publisher-id">OJOG-130531</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Retro Placental Hematoma: Maternal and Fetal Prognosis at the Maternity of the University Hospital of Bouake
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Samake</surname><given-names>Yaya</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Djanhan</surname><given-names>Lydie Estelle</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Menin-Messou</surname><given-names>Benie Michele</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kouadio</surname><given-names>Kouadio Narcisse</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Akanji</surname><given-names>Iburaima Alamun</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>M’bro</surname><given-names>Clausen Georgie</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Boko</surname><given-names>Dagoun Dagbesse Elysee</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Camara</surname><given-names>Sokhona</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>N’guessan</surname><given-names>Kouadio Ismael</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Foua</surname><given-names>Bi Paul Hyacinthe</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Keita</surname><given-names>Ismael</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Vaho</surname><given-names>Magnificat Marina</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kone</surname><given-names>Minzata Yasmine</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Doumbia</surname><given-names>Yacouba</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>Mother and Child Department, Alassane Ouattara University, Bouake, Ivory Coast</addr-line></aff><aff id="aff1"><addr-line>Gynaecology-Obstetrics Department, Centre Hospitalier Universitaire de Bouaké, Bouake, Ivory Coast</addr-line></aff><pub-date pub-type="epub"><day>09</day><month>01</month><year>2024</year></pub-date><volume>14</volume><issue>01</issue><fpage>44</fpage><lpage>56</lpage><history><date date-type="received"><day>10,</day>	<month>December</month>	<year>2023</year></date><date date-type="rev-recd"><day>14,</day>	<month>January</month>	<year>2024</year>	</date><date date-type="accepted"><day>17,</day>	<month>January</month>	<year>2024</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Introduction
  : 
  Retroplacental haematoma (RPH) is a very serious complication of pregnancy, with life-threatening consequences for both the mother and foetus. The aim of this study is to determine the incidence and epidemiological characteristics of patients with retroplacental haematoma (RPH) and describe the maternal-foetal complications at Bouak&#233; University Hospital. <b>Methods:</b> This was a cross-sectional prospective, descriptive and analytical study carried out at Bouak&#233; University Hospital over a period of 3 years, from January 1, 2019 to December 31, 2021. All parturients with RPH whose delivery took place at the hospital were included in the study. Data were entered and analysed using EPI INFO software version 7.2.2.6. <b>Results:</b> We recorded 2
  ,
  0959 deliveries, including 202 cases of RPH, representing an incidence of 0.96%. The 21 to 35 age group accounted for 64.4%, multigestas and large multigestas accounted for 58.5% and multiparas accounted for 41.6%. The main signs on clinical examination were metrorrhagia (100%), arterial hypertension (84.6%) and cervical cerclage (79.7%). Preeclampsia accounted for 50% of per-gestational pathologies. Maternal mortality was 12.9%. Morbidity was dominated by anaemia in 64.1%, followed by disseminated intravascular coagulation (DIC) in 21.8%, and the 
  factors associated with this maternal prognosis were multiple gestations, multiparity, Sher grade IIIb and the occurrence of complications such as DIC, shock, renal complications and HELLP syndrome. Neonatal mortality was 79.2%, and the factors associated with these fetal prognoses were cup size ≥
   
  5 cm and hematoma weight ≥
   
  500 g.
   <b>Conclusion: </b>Better screening of at-risk populations, early diagnosis and treatment in an organised and equipped medical and surgical facility would improve prognosis.
 
</p></abstract><kwd-group><kwd>Retroplacental Haematoma</kwd><kwd> Lethality</kwd><kwd> Bouak&#233; and Prognosis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Retroplacental haematoma (RPH) is a very serious complication of pregnancy, with life-threatening consequences for both the mother and foetus. Retroplacental haematoma (RPH) is a paroxysmal syndrome in the last months of pregnancy or labour, characterised anatomically by a haematoma located between the placenta and the uterine wall; this haemorrhagic state can range from the simple bursting of an infarct on the surface of the placenta to haemorrhagic raptus affecting the entire genital area and even extending beyond it [<xref ref-type="bibr" rid="scirp.130531-ref1">1</xref>] . It is one of the major causes of haemorrhage in the third trimester of pregnancy. Haemorrhage is the leading cause of maternal death, accounting for 500,000 deaths worldwide according to the WHO [<xref ref-type="bibr" rid="scirp.130531-ref2">2</xref>] . Placental abruption is responsible for 20% - 25% of antepartum haemorrhages [<xref ref-type="bibr" rid="scirp.130531-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.130531-ref4">4</xref>] . It is also associated with an increased risk of disseminated intravascular coagulopathy, maternal shock, and renal failure and is one of the main causes of postpartum hemorrhage [<xref ref-type="bibr" rid="scirp.130531-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.130531-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.130531-ref6">6</xref>] . It remains an unpredictable pathology despite the recognised risk factors: extreme maternal age, multiparity, black race, a history of PRH, thrombophilia, drug use, high blood pressure (hypertension) and the occurrence of direct shock to the abdomen [<xref ref-type="bibr" rid="scirp.130531-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.130531-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.130531-ref8">8</xref>] . RPH sometimes occurs in the absence of these risk factors. In developing countries, abruptio placenta is related to about 1% of maternal mortality with significant prenatal mortality and morbidity about 7% to 20% [<xref ref-type="bibr" rid="scirp.130531-ref3">3</xref>] . Despite the seriousness of this condition, we have no up-to-date data for Bouak&#233;. With this in mind, we are conducting this study to determine the prevalence and epidemiological characteristics of patients with RPH and to describe the maternal-fetal complications at Bouak&#233; University Hospital.</p></sec><sec id="s2"><title>2. Methods</title><sec id="s2_1"><title>2.1. Study Design and Setting</title><p>This was a cross-sectional prospective, descriptive and analytical study conducted over a period of 3 years, from the 1<sup>st</sup> of January 2019 to the 31<sup>st</sup> of December 2021. It took place in the obstetrics and gynaecology department of Bouak&#233; University Hospital. The city of Bouak&#233; is located in the centre of Ivory Coast and is the second most populous city after Abidjan, with a general population estimated at 1,542,000 according to the MICS 2021 [<xref ref-type="bibr" rid="scirp.130531-ref9">9</xref>] . The city has a university hospital, which is a tertiary-level hospital according to the country’s health pyramid. The centre has a gynaecology department, which provides medical and surgical care for Gynaecological and Obstetric pathologies. It is a referral service, receiving patients referred from general and peripheral hospitals in the town of Bouak&#233;, as well as from surrounding towns in the centre, north and west of the country. The maternity ward in the Gynaecology and Obstetrics department has 4 delivery cubicles, 6 post-natal beds and an operating theatre with two operating theatres. The daily team consists of a Gynaecologist Obstetrician, three medical doctors with a diploma in Gynaecology and Obstetrics, four midwives and two nurses.</p></sec><sec id="s2_2"><title>2.2. Study Population</title><p>The study population consisted of all parturients with 28 or more weeks of gestation, admitted to the delivery room in the department. Sampling was exhaustive. All parturients with RPH whose delivery took place at the university hospital were included in the study, regardless of their origin, and all cases of RPH were confirmed after delivery by the presence of haematomas or cupules. We did not include in the study patients admitted on suspicion of RPH but in whom the examination did not reveal any placental cup and patients who did not give their consent.</p></sec><sec id="s2_3"><title>2.3. Data Collection and Analysis</title><p>The variables studied were sociodemographic characteristics, course of pregnancy, delivery and neonatal parameters. The questionnaire was developed after reviewing different literatures. The data were entered into a computer and analysed using EPI INFO software version 7.2.2.6 with the use of Chi-squared statistical tests for numbers ≥ 5 and Fisher for numbers &lt; 5 with α = 5%. A P-value of less than 0.05 was considered to be statistically significant. Descriptive statistics were used to describe the characteristics of the study respondents by using means and standard deviations for numerical variables, frequencies along with percentages for categorical variables and table.</p></sec></sec><sec id="s3"><title>3. Results</title><sec id="s3_1"><title>3.1. Incidence</title><p>During the study period, we recorded 20,959 deliveries at the Bouak&#233; University Hospital maternity unit, including 202 cases of RPH, representing an incidence of 0.96%.</p></sec><sec id="s3_2"><title>3.2. Epidemiological Characteristics</title><p>The mean age was 29.8 &#177; 7.2 years, with extremes of 15 and 45 years. The 21 - 35 age group accounted for 64.4% of cases. The patients were in a couple in 90.1% of cases and had domestic activity in 63.9% of cases. Large multigestations and multigestations accounted for 58.5% of cases. The average parity was 4, with extremes of 0 and 12. Multiparous and large multiparous males accounted for 41.6% of cases. Nulliparous women accounted for 21.8%. Of the 202 patients, 10 (5%) had not had a pregnancy follow-up. Of those with a pregnancy follow-up, 62.9% had undergone less than the mandatory 4 parental consultations (ANCs). Only one of the 202 patients had a history of RPH. Patients were referred from a public health facility in 87.6% of cases. The reasons for evacuation were dominated by 3<sup>rd</sup> trimester metrorrhagia, RPH and uterine contractures in 51.5%, 18.2% and 10.4% of patients, respectively.</p></sec><sec id="s3_3"><title>3.3. Clinical Aspects</title><p>Gestational age was between 37 and 41 SA + 6 days in 48.1% of cases. Mono-foetal pregnancies accounted for 98.5%. Clinical signs on admission were dominated by metrorrhagia (100%), uterine contracture (98.5%), cervical cerclage (79.7%) and absent foetal heart sounds (83.1%) at the obstetrical level. General symptoms included hypertension in 84.6% of cases, proteinuria (45.5%) and shock (11.4%). RPH was classified as Sher grade III in 80% of cases, including 72.8% as grade IIIa. Grades 1 and 2 accounted for 3.5% and 17.3%, respectively. Caesarean section was the mode of delivery in 82.2% of patients. The mean time from admission to delivery was 51.3 &#177; 42.3 minutes, with extremes of [15 minutes - 4 hours]. On examination of the placenta, the mean cup size was 6.8 &#177; 2.2 cm with a range of [3 - 16 cm], and the cup size was greater than or equal to 5 in 88.1% of cases. The mean weight of the haematoma was 504.8 &#177; 245 g [100 - 1500 g].</p></sec><sec id="s3_4"><title>3.4. Variables Related to Maternal Prognosis</title><p>During the study period, there were 26 maternal deaths, representing a case-fatality rate of 12.9%. Factors statistically associated with maternal death were multigestity (p = 0.04), multiparity (p = 0.01), Sher grade IIIb (p = 0.0001) and the occurrence of complications such as DIC (p = 0.0001), shock (p = 0.0001), renal complications (p = 0.002) and HELLP syndrome (p = 0.0001) (<xref ref-type="table" rid="table1">Table 1</xref>). Maternal morbidity related to RPH was dominated by anemia in 64.1% of cases, followed by DIC in 21.8% and postpartum infection in 5.1%.</p></sec><sec id="s3_5"><title>3.5. Variables Related to Neonatal Prognosis</title><p>During the study period, neonatal case fatality was 79.2%. Factors statistically associated with foetal mortality were cup size ≥ 5 cm (p = 0.0001) and haematoma weight ≥ 500 g (p = 0.0001) (<xref ref-type="table" rid="table2">Table 2</xref>). Foetal weight was between 1501 and 2500 g in 45.5% of cases. The Apgar score at the 5<sup>th</sup> minute of life was less than 3 in 81.2% of cases. Of the live neonates, 71.4% were transferred to the neonatology unit.</p></sec></sec><sec id="s4"><title>4. Discussion</title><p>In order to study retroplacental hematoma at Bouak&#233; University Hospital, we carried out this prospective study in the gynecology-obstetrics department. It</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Distribution of patients according to factors associated with maternal prognosis</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  ></th><th align="center" valign="middle"  colspan="2"  >Maternal prognosis</th><th align="center" valign="middle"  rowspan="2"  >p value</th></tr></thead><tr><td align="center" valign="middle" >Dead</td><td align="center" valign="middle" >Alive</td></tr><tr><td align="center" valign="middle" >Age</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≤35 ans</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >139</td><td align="center" valign="middle" >0.122</td></tr><tr><td align="center" valign="middle" >&gt;35 ans</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >37</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Gestity</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≤3</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >78</td><td align="center" valign="middle" >0.04</td></tr><tr><td align="center" valign="middle" >&gt;3</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >98</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Parity</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≤3</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >109</td><td align="center" valign="middle" >0.01</td></tr><tr><td align="center" valign="middle" >&gt;3</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >67</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Antenatal care</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≤3</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >112</td><td align="center" valign="middle" >0.558</td></tr><tr><td align="center" valign="middle" >&gt;3</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >64</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Mode of admission</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Not referred</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >0.646</td></tr><tr><td align="center" valign="middle" >Referred</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >153</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Cup size</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;5 cm</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >0.554</td></tr><tr><td align="center" valign="middle" >≥5 cm</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >156</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Weight of hematoma</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;500</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >83</td><td align="center" valign="middle" >0.406</td></tr><tr><td align="center" valign="middle" >500 - 1000</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >91</td><td align="center" valign="middle" >0.348</td></tr><tr><td align="center" valign="middle" >&gt;1000</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >Classification of Sher</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >I</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >0.502</td></tr><tr><td align="center" valign="middle" >II</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >0.183</td></tr><tr><td align="center" valign="middle" >IIIa</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >132</td><td align="center" valign="middle" >0.06</td></tr><tr><td align="center" valign="middle" >IIIb</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >&lt;0.0001</td></tr><tr><td align="center" valign="middle" >Complications</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Persistent anaemia</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >86</td><td align="center" valign="middle" >0.321</td></tr><tr><td align="center" valign="middle" >DIC</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >&lt;0.0001</td></tr><tr><td align="center" valign="middle" >Shock</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >&lt;0.0001</td></tr><tr><td align="center" valign="middle" >Renal complication</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0.002</td></tr><tr><td align="center" valign="middle" >HELLP Syndrome</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >&lt;0.0001</td></tr></tbody></table></table-wrap><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Distribution of patients according to factors associated with foetal prognosis</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  ></th><th align="center" valign="middle"  colspan="2"  >Fetal prognosis</th><th align="center" valign="middle"  rowspan="2"  >p value</th></tr></thead><tr><td align="center" valign="middle" >Stillborn</td><td align="center" valign="middle" >Alive</td></tr><tr><td align="center" valign="middle" >Gestationnal age</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;37 SA (week of amenorrhoea)</td><td align="center" valign="middle" >89</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >0.860</td></tr><tr><td align="center" valign="middle" >≥37 SA</td><td align="center" valign="middle" >71</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Mother admission mode</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Not referred</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >0.140</td></tr><tr><td align="center" valign="middle" >Referred</td><td align="center" valign="middle" >143</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Newborn weight</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;1500 g</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >0.620</td></tr><tr><td align="center" valign="middle" >≥1500 g</td><td align="center" valign="middle" >132</td><td align="center" valign="middle" >36</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Cup size</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;5 cm</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >&lt;0.0001</td></tr><tr><td align="center" valign="middle" >≥5 cm</td><td align="center" valign="middle" >154</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Hematoma weight</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;500 g</td><td align="center" valign="middle" >63</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >&lt;0.0001</td></tr><tr><td align="center" valign="middle" >≥500 g</td><td align="center" valign="middle" >97</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >admission-delivery delay</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≤60 minutes</td><td align="center" valign="middle" >92</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >0.427</td></tr><tr><td align="center" valign="middle" >≥60 minutes</td><td align="center" valign="middle" >68</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>enabled us to describe the sociodemographic and clinical characteristics of pregnant women, to determine the prevalence of retroplacental hematoma and to describe maternal-fetal complications. The limitations of this study could be information bias, due to the fact that the data were collected from respondents using a self-administered questionnaire, and that it was impossible to verify the information provided.</p><sec id="s4_1"><title>4.1. Incidence</title><p>During the study, we recorded 20,959 deliveries at the Bouak&#233; University Hospital maternity ward, including 202 cases of RPH, giving an incidence of 0.96%. Our incidence is comparable to those of Budak and Igwebe, who found 0.66% and 0.8%, respectively [<xref ref-type="bibr" rid="scirp.130531-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.130531-ref11">11</xref>] . However, it is lower than those reported in Nigeria, India and C&#244;te d’Ivoire [<xref ref-type="bibr" rid="scirp.130531-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.130531-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.130531-ref14">14</xref>] , which were 1.46%, 3.9% and 4.4%, respectively. This difference could be explained by the type of study, the diagnostic criteria and the study populations.</p></sec><sec id="s4_2"><title>4.2. Epidemiological Characteristics</title><p>The 21 - 35 age group was the most represented (64.4%), with an average age of 29.8 years. The same trends have been reported by other authors for the mean age: 29 years for O Thiam in Senegal [<xref ref-type="bibr" rid="scirp.130531-ref3">3</xref>] and 29.14 for N Adewole in Nigeria [<xref ref-type="bibr" rid="scirp.130531-ref15">15</xref>] . Different authors [<xref ref-type="bibr" rid="scirp.130531-ref16">16</xref>] [<xref ref-type="bibr" rid="scirp.130531-ref17">17</xref>] have assessed the role of maternal age in the occurrence of PRH differently. According to the literature, the risk between maternal age and RPH was linked only by parity [<xref ref-type="bibr" rid="scirp.130531-ref17">17</xref>] . Patients’ professional occupations may constitute an obstacle to access to care. In our study, 63.9% of patients had no fixed income. This is twice as high as in the N adewole study in Nigeria [<xref ref-type="bibr" rid="scirp.130531-ref15">15</xref>] . According to Nayama [<xref ref-type="bibr" rid="scirp.130531-ref18">18</xref>] , low socioeconomic status is a risk factor for RPH. RPH appears to be a pregnancy pathology that spares no parity. However, multiparous women were the most common in our series (41.6%). Multiparity is a known risk factor for RPH [<xref ref-type="bibr" rid="scirp.130531-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.130531-ref19">19</xref>] . The risk of occurrence increases with the number of pregnancies and becomes considerable from the fifth parity onwards [<xref ref-type="bibr" rid="scirp.130531-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.130531-ref19">19</xref>] . Thieba [<xref ref-type="bibr" rid="scirp.130531-ref20">20</xref>] in Burkina Faso asserted that the increase in the prevalence of RPH in pregnant women, and in particular in primiparous and young pregnant women, was linked to insufficient or inadequate monitoring of pregnancy, rather than to the existence of hypertension or previous renal damage. In our study, nulliparous women accounted for 21.8%. This may be explained by the fact that multiparity favours the occurrence of RPH because of alterations in the uterine mucosa, and primiparity favours the occurrence of toxaemia gravidarum. In our series, more than half of the patients (62.9%) had not undergone the required number of antenatal consultations. According to the literature, the frequency of RPH tends to decrease as the number of ANCs increases, and poor antenatal surveillance is a factor predisposing patients to RPH [<xref ref-type="bibr" rid="scirp.130531-ref18">18</xref>] . Pregnant women were referred from a public health facility in 87.6% of cases, and the same finding was made by Ousmane thiam in Senegal [<xref ref-type="bibr" rid="scirp.130531-ref21">21</xref>] , which was 66%, and Godwin s in Tanzania [<xref ref-type="bibr" rid="scirp.130531-ref8">8</xref>] (46%). This high frequency of patients being evacuated could be explained on the one hand by the fact that our facility is the only public facility in Bouak&#233; performing complete emergency obstetric and neonatal care.</p></sec><sec id="s4_3"><title>4.3. Clinical Aspects</title><p>RPH was classified as Sher III in 80.7% of cases, including 72.8% as grade IIIa. Our results are similar to those of F Abedlkader in Mauritania [<xref ref-type="bibr" rid="scirp.130531-ref17">17</xref>] , who found 86.5%, but higher than those of O thiam in Senegal [<xref ref-type="bibr" rid="scirp.130531-ref21">21</xref>] , who found 63%, and J Coleman in Ghana [<xref ref-type="bibr" rid="scirp.130531-ref22">22</xref>] who found 53%, which could be explained by the delay in consultation, thus worsening the maternal-fetal prognosis. Gestational age was full term in 48.1% of cases. The labor of O thiam in Senegal [<xref ref-type="bibr" rid="scirp.130531-ref21">21</xref>] was approximately 36 SA and F adelkader [<xref ref-type="bibr" rid="scirp.130531-ref17">17</xref>] at a gestational age of 34.7. However, Nayama in Niger [<xref ref-type="bibr" rid="scirp.130531-ref18">18</xref>] found cases of RPH between 20 and 27 weeks of gestation (2.5%). It should therefore be considered in pregnant women with risk factors when the pregnancy is at least 20 days gestation.</p></sec><sec id="s4_4"><title>4.4. Variables Related to Maternal Prognosis</title><p>Maternal mortality was 12.9% in our study, which is much higher than the results of Godwin in Tanzania [<xref ref-type="bibr" rid="scirp.130531-ref8">8</xref>] at 3.6%, J Coleman in Ghana [<xref ref-type="bibr" rid="scirp.130531-ref22">22</xref>] at 2% and Doumbia in C&#244;te d’Ivoire [<xref ref-type="bibr" rid="scirp.130531-ref14">14</xref>] at 2.9%. Morbidity was represented by anaemia in 64.1% of cases, which is higher than the study by O Thiam in Senegal [<xref ref-type="bibr" rid="scirp.130531-ref21">21</xref>] , who found 17.8%. This could be explained by the lack of blood products in our health facilities. The factors statistically associated with maternal death were multiple gestations, multiple pregnancies, Sher grade IIIb and the occurrence of complications such as DIC, shock, renal complications and HELLP syndrome.</p></sec><sec id="s4_5"><title>4.5. Variables Related to Neonatal Prognosis</title><p>Fetal weight was between 1501 and 2500 g in 45.5% of cases, whereas F Abdelkader in Mauritania [<xref ref-type="bibr" rid="scirp.130531-ref17">17</xref>] found a fetal weight of less than 1500 g in 46.39% of cases. Neonatal mortality was 79.2%, similar to the study by Doumbia [<xref ref-type="bibr" rid="scirp.130531-ref14">14</xref>] at 78.6% but higher than O Thiam in Senegal [<xref ref-type="bibr" rid="scirp.130531-ref21">21</xref>] at 60.5%, which could be explained by the severity of the clinical picture but also by the low weight of the foetuses, reflecting their fragility. Newborns presented a malformation in 1.5% of cases. Of the live newborns, 71.4% were transferred to the neonatology unit. The factors statistically associated with foetal mortality were cup size ≥ 5 cm and haematoma weight ≥ 500 g.</p></sec></sec><sec id="s5"><title>5. Conclusion</title><p>Because of its brutality and the severity of its maternal and foetal consequences, RPH is a medical and obstetric emergency par excellence. Better screening of at-risk populations, early diagnosis and treatment in an organised and equipped medical and surgical facility would improve the prognosis.</p></sec><sec id="s6"><title>Authors’ Contributions</title><p>All authors have read and approved the final version of the manuscript.</p></sec><sec id="s7"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s8"><title>Cite this paper</title><p>Yaya, S., Estelle, D.L., Michele, M.-M.B., Narcisse, K.K., Alamun, A.I., Georgie, M.C., Elysee, B.D.D., Sokhona, C., Ismael, N.K., Hyacinthe, F.B.P., Ismael, K., Marina, V.M., Yasmine, K.M. and Yacouba, D. (2024) Retro Placental Hematoma: Maternal and Fetal Prognosis at the Maternity of the University Hospital of Bouake. Open Journal of Obstetrics and Gynecology, 14, 44-56. https://doi.org/10.4236/ojog.2024.141006</p></sec><sec id="s9"><title>Survey Sheet</title><p>RETRO PLACENTAL HEMATOMA: Maternal-fetal prognosis at the maternity ward of the Centre Hospitalier Universitaire de Bouak&#233;</p><p>File no.:</p>I. General Information<p>Age: ...................</p><p>Geographical origin: Urban &#168; Rural &#168;</p><p>Profession: Civil servant &#168; Housewife &#168; Student &#168;</p><p>Tradeswoman &#168; Other &#168;</p><p>Marital status: Married &#168; Single &#168;</p>II. Background<p>Medical: .................................................................</p><p>Surgical: ........................................................................</p><p>Toxic: Alcohol &#168; tobacco &#168; other drugs &#168;</p><p>Gyneco-obstetrical:</p><p>- Gestit&#233;: .................................</p><p>- Parity:...............................</p><p>- Gynecological history:</p><p>Spontaneous abortion Fetal Death In Utero &#168;</p><p>- Obstetrical history:</p><p>Caesarean section &#168; Threatened premature delivery &#168;</p><p>Premature rupture of membranes &#168; Retroplacental hematoma &#168;</p><p>Delivery hemorrhage &#168;</p>III. Current Pregnancy<p>Prenatal follow-up:</p><p>Urban Health Center/Rural Health Center &#168; Private clinic &#168;</p><p>Not followed &#168; Regional Hospital &#168; University Hospital &#168;</p><p>General Hospital &#168;</p><p>Number of prenatal consultations: .........................</p><p>Number of fetuses: ...................</p><p>Complications:</p><p>1<sub>st</sub> and 2<sub>nd</sub> trimester hemorrhage &#168; Anemia &#168; Gestational diabetes &#168;</p><p>Threat of premature delivery &#168; Premature rupture of membranes &#168;</p><p>Hypertension-preclampsia &#168; eclampsia &#168;</p>IV. Admission<p>Mode of admission:</p><p>Referred from another center &#168; Not referred &#168;</p><p>Reason for admission:</p><p>Hemorrhagic shock &#168; Delivery &#168; Uterine contractures &#168;</p><p>Metrorrhagia &#168; Absence of BDCF &#168; Preeclampsia &#168;</p><p>Eclampsia &#168; Trauma &#168; Gestational arterial hypertension &#168; Threat of preterm delivery &#168; Retroplacental hematoma &#168;</p>V. Clinical Examination<p>General examination:</p><p>General condition: good &#168; Shock &#168;</p><p>- Blood pressure: systole: ...................diastole:........................</p><p>- Edema: Yes &#168; No &#168;</p><p>- Urinary dipstick: ...................</p><p>Obstetrical examination:</p><p>- Uterine height: ...................</p><p>- Fetal heart sounds: absent &#168; present &#168;</p><p>- Uterine contraction: Yes &#168; No &#168;</p><p>- Uterine hypertonia: Yes &#168; No &#168;</p><p>- Metrorrhagia: Yes &#168; No &#168; Appearance: ............ Quantity: ..............</p><p>- Cervical condition: ............................ Dilatation ........................................</p><p>- Water status: Intact &#168; Broken &#168;</p><p>Fetal presentation: Seated &#168; Cephalic &#168; Transverse &#168;</p><p>SHER classification: I: II: IIIa: IIIb:</p>VI. Additional Tests<p>Biology:</p><p>hemoglobin: .................... Platelets: ...................... Prothrombin rate: ..................</p><p>activated partial thromboplastin rate: ..........................</p><p>Fibrin degradation products: ............................... Fibrinogen: ..............</p><p>Blood urea: .......................... Creatinine: ......................</p><p>GOT/GPT: ................. 24-hour proteinuria: .........</p>VII. Maternal Prognosis<p>Mortality: Yes &#168; No &#168;</p><p>Morbidity:</p><p>Persistent anemia &#168; Disseminated intravascular coagulation &#168;</p><p>Hemorrhagic shock state &#168;</p><p>Renal complication &#168; HELLP syndrome &#168; Delivery hemorrhage &#168;</p><p>Uterine atony &#168; Chorioamniotitis &#168;</p><p>Post-partum infection &#168; Thrombophlebitis &#168;</p><p>Cardiac damage &#168; Neurological damage &#168;</p><p>Length of hospital stay (days):..................................</p>IX. Fetal Prognosis<p>Fetal characteristics:</p><p>- Term of delivery: ............................</p><p>- Birth weight: ............................</p><p>- Sex: Male &#168; Female &#168;</p><p>Mortality: Stillborn &#168; Alive &#168;</p><p>Morbidity:</p><p>- APGAR score: ............................</p><p>- Respiratory distress: Yes &#168; No &#168;</p><p>- Congenital malformation: Yes &#168; No &#168;</p><p>Transfer to intensive care: Yes &#168; No &#168;</p><p>Transfer to pediatrics: Yes &#168; No &#168;</p></sec></body><back><ref-list><title>References</title><ref id="scirp.130531-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Lansac, J., Berger, C. and Magnin, G. (1997) Obstétrique pour le praticien. 3e édition, MASSON, Paris.</mixed-citation></ref><ref id="scirp.130531-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">OMS, UNICEF, FNUAP and BANQUE MONDIALE (2007) Mortalite maternelle en 2005 Organisation mondiale de la santé. Geneve.</mixed-citation></ref><ref id="scirp.130531-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Tikkanen, M. (2011) Placental Abruption: Epidemiology, Risk Factors and Consequences. Acta Obstetricia et Gynecologica Scandinavica, 90, 140-149.  
https://doi.org/10.1111/j.1600-0412.2010.01030.x</mixed-citation></ref><ref id="scirp.130531-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Hall, D.R. (2009) Abruptio Placentae and Disseminated Intravascular Coagulopathy. Seminars in Perinatology, 33, 189-195.  
https://doi.org/10.1053/j.semperi.2009.02.005</mixed-citation></ref><ref id="scirp.130531-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Jabeen, M. and Gul, F. (2011) Abruptio Placentae: Risk Factors and Perinatal Outcome. Journal of Postgraduate Medical Institute, 18, 669-676.</mixed-citation></ref><ref id="scirp.130531-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Sarwar, I., Abbas, A. and Islam, A. (2006) Abruptio Placentae and Its Complication at Ayub Teaching Hospital Abbotabad. Journal of Ayub Medical College Abbottabad, 18, 27-31.</mixed-citation></ref><ref id="scirp.130531-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Sananes, N., Boisrame, T. and Langer, B. (2012) Hématome rétroplacentaire. EMC—Obstétrique, 7, 1-11. https://doi.org/10.1016/S0246-0335(12)50196-1</mixed-citation></ref><ref id="scirp.130531-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Macheku, G.S., Philemon, R.N., Oneko, O., Mlay, P.S., Masenga, G., Obure, J., et al. (2015) Frequency, Risk Factors and Feto-Maternal Outcomes of Abruption Placentae in Northern Tanzania: à Registry-Based Retrospective Cohort Study. BMC Pregnancy Childbirth, 15, Article No. 242. https://doi.org/10.1186/s12884-015-0678-x</mixed-citation></ref><ref id="scirp.130531-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">(2023) Resultats globaux definitifs du rgph 2021: La population vivant habituellement sur le territoire ivoirien se chiffre a 29 389 150 habitants.  
https://www.gouv.ci/_actualite-article.php?recordID=13769</mixed-citation></ref><ref id="scirp.130531-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Budak, M.&amp;#350;., &amp;#350;entürk, M.B., &amp;#199;akmak, Y., Polat, M., Do&amp;#287;an, O. and Pulato&amp;#287;lu, &amp;#199;. (2018) Risk Factors and Outcomes of Placental Abruption: Evaluation of 53 Cases. The Medical Bulletin of Haseki, 56, 203-208. https://doi.org/10.4274/haseki.3999</mixed-citation></ref><ref id="scirp.130531-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Igwegbe, A.O., Eleje, G.U. and Okpala, B.C. (2013) Management Outcomes of Abruptio Placentae at Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria. Nigerian Journal of Medicine, 22, 234-238.</mixed-citation></ref><ref id="scirp.130531-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Abasi, I.J., Israel, J. and Ekine, A.A. (2015) Risk Factors and Pregnancy Outcome of Placental Abruption at the Niger Delta University Teaching Hospital, Okolobiri, South-South Nigeria. British Journal of Medicine and Medical Research, 5, 1000-1006.  
https://doi.org/10.9734/BJMMR/2015/12842</mixed-citation></ref><ref id="scirp.130531-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Mukherjee, S., Bawa, A.K., Sharma, S., Nandanwar, Y.S. and Gadam, M. (2014) Retrospective Study of Risk Factors and Maternal and Fetal Outcome in Patients with Abruptio Placentae. Journal of Natural Science, Biology, and Medicine, 5, 425-428.  
https://doi.org/10.4103/0976-9668.136217</mixed-citation></ref><ref id="scirp.130531-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Doumbia, Y., Kouakou, K.P., Djanhan, L.E., Menin, M.M., Kone, D.D.A. and Djanhan, Y. (2013) L’hématome rétroplacentaire au CHU de Bouaké: à propos de 524 cas. Journal de la SAGO, 14, 39-44.</mixed-citation></ref><ref id="scirp.130531-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Adewole, N., Isah, A.D. and Osinachi, I.F. (2019) Foeto-Maternal Outcome of Abruptio Placentae at a Nigerian Tertiary Hospital. African Journal of Medical and Health Sciences, 18, 18-24.</mixed-citation></ref><ref id="scirp.130531-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Downes, K.L., Grantz, K.L. and Shenassa, E.D. (2017) Maternal, Labor, Delivery, and Perinatal Outcomes Associated with Placental Abruption: A Systematic Review. American Journal of Perinatology, 34, 935-957.  
https://doi.org/10.1055/s-0037-1599149</mixed-citation></ref><ref id="scirp.130531-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Abdelkader, F., Abdelkader, N. and Vall Malek, M. (2019) Hematome retro placentaire aspects epidemiologiques cliniques, therapeutiques et pronostiques au centre hospitalier national à propos de 97 cas. International Journal of Advanced Research, 7, 785-789. https://doi.org/10.21474/IJAR01/10211</mixed-citation></ref><ref id="scirp.130531-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Nayama, M., Tamakloe Azamesu, D., Garba, M., Idi, N., Djibril, B., et al. (2007) Abruption Placentae Management in a Reference Nigerien Maternity: Prospective Study Approximately 118 Cases during One Year. Gynécologie Obstétrique &amp; Fertilité, 35, 975-981. https://doi.org/10.1016/j.gyobfe.2007.05.023</mixed-citation></ref><ref id="scirp.130531-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Dumont, A., De Bernis, L., Decame, C., Ba, M. and Pollet, X. (1996) Indicateurs de la coagulation intravasculaire disséminée (CIVD) dans les H R P. Médecine Afrique Noire, 43, 6-11.</mixed-citation></ref><ref id="scirp.130531-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Thieba, B., Ouattara, T., Kyeleme, C., Ouedraogo, C.M.C., et al. (2001) L’hématome retroplacentaire dans le Service de Gynécologie-Obstétrique de CHNYO de Ouagadougou: Aspects épidémio-cliniques et pronostiques. Journal de la SAGO, 1, 10-14.</mixed-citation></ref><ref id="scirp.130531-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Thiam, O., Mbaye, M., Diouf, A.A., Touré, F.B., Gueye, M., Niang, M., et al. (2014) Aspects épidémiologiques, pronostiques et thérapeutiques de l’hématome retro placentaire (RPH) dans une maternité de référence en zone rurale. Pan African Medical Journal, 17, Article 11. https://doi.org/10.11604/pamj.2014.17.11.3554</mixed-citation></ref><ref id="scirp.130531-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Coleman, J., Srofenyo, E.K., Ofori, E.K., Brakohiapa, E.K. and Antwi, W.K. (2014) Maternal and Fetal Prognosis in Abruptio Placentae at Korle-Bu Teaching Hospital, Ghana. African Journal of Reproductive Health, 18, 115-122.</mixed-citation></ref></ref-list></back></article>